CASE REPORTS  THORACIC PAPERS 

The Journal of Cardiovascular Surgery 2000 October;41(5):773-6

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Long-term survival of patients treated with octreotide for metastatic well differentiated neuroendocrine carcinoma of the lung

Filosso P. L., Croce S., Oliaro A., Ruffini E.

From the Department of Thoracic Surgery *Department of Biomedical Sciences and Human Oncology University of Turin, Turin, Italy

Two ­patients ­with a rad­i­cal­ly oper­at­ed ­well dif­fer­en­tiat­ed neu­ro­en­do­crine car­ci­no­ma (­WDNC) of the ­lung who devel­oped a car­ci­noid syn­drome due to met­a­stat­ic ­spread of the ­tumor are report­ed. Treatment ­with som­a­tos­ta­tin ana­logue octre­o­tide was admin­is­tered to ­both ­patients fol­low­ing ­their refu­sal of a stan­dard chem­o­the­rap­ic reg­i­men. Prompt res­o­lu­tion of the car­ci­noid syn­drome was ­observed in ­both fol­low­ing octre­o­tide treat­ment and ­both ­patients are ­alive and ­well ­after ­more ­than four ­years with­out evi­dence of fur­ther pro­gres­sion of the ­tumor. It is sug­gest­ed ­that oc­tre­o­tide ­should be con­sid­ered as an effec­tive ther­a­py in ­WDNC for the con­trol of the dis­ease and asso­ciat­ed par­a­neo­plas­tic syn­dromes.